Lynx1 Capital Management

Lynx1 Capital Management as of March 31, 2024

Portfolio Holdings for Lynx1 Capital Management

Lynx1 Capital Management holds 15 positions in its portfolio as reported in the March 2024 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Alpine Immune Sciences 23.2 $89M 2.3M 39.64
Merus N V (MRUS) 17.6 $68M 1.5M 45.03
Stoke Therapeutics (STOK) 12.9 $50M 3.7M 13.50
Tscan Therapeutics (TCRX) 10.8 $42M 5.2M 7.94
Cabaletta Bio (CABA) 9.2 $36M 2.1M 17.06
Gh Research Ordinary Shares (GHRS) 9.1 $35M 3.3M 10.66
C4 Therapeutics Com Stk (CCCC) 7.7 $30M 3.6M 8.17
Silence Therapeutics Ads (SLN) 2.9 $11M 527k 21.60
Autolus Therapeutics Spon Ads (AUTL) 2.3 $8.9M 1.4M 6.38
Passage Bio (PASG) 1.7 $6.5M 4.8M 1.35
Kinnate Biopharma 1.4 $5.3M 2.0M 2.66
Nektar Therapeutics (NKTR) 0.5 $1.9M 2.1M 0.93
Pieris Pharmaceuticals 0.4 $1.6M 8.8M 0.18
Bionomics Ads (BNOX) 0.2 $839k 815k 1.03
Centessa Pharmaceuticals Sponsored Ads (CNTA) 0.1 $197k 17k 11.30